333 related articles for article (PubMed ID: 23801585)
1. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
3. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
[TBL] [Abstract][Full Text] [Related]
5. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
[TBL] [Abstract][Full Text] [Related]
8. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Giladi N; Boroojerdi B; Surmann E
J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
Parkinson Study Group
Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
[TBL] [Abstract][Full Text] [Related]
10. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Watts RL; Jankovic J; Waters C; Rajput A; Boroojerdi B; Rao J
Neurology; 2007 Jan; 68(4):272-6. PubMed ID: 17202432
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
12. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
Jankovic J; Watts RL; Martin W; Boroojerdi B
Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
[TBL] [Abstract][Full Text] [Related]
13. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
[TBL] [Abstract][Full Text] [Related]
14. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
[TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
[TBL] [Abstract][Full Text] [Related]
17. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
Nomoto M; Iwaki H; Kondo H; Sakurai M
J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
[TBL] [Abstract][Full Text] [Related]
19. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]